DUBLIN--(BUSINESS WIRE)--The "Dyslipidemia - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
Report Highlights
This Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dyslipidemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 26, 16, 26, 33, 7 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 12 and 4 molecules, respectively.
Dyslipidemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Dyslipidemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dyslipidemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dyslipidemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia (Metabolic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Introduction
- Dyslipidemia - Overview
- Dyslipidemia - Therapeutics Development
- Dyslipidemia - Therapeutics Assessment
- Dyslipidemia - Companies Involved in Therapeutics Development
- Dyslipidemia - Drug Profiles
- Dyslipidemia - Dormant Projects
- Dyslipidemia - Discontinued Products
- Dyslipidemia - Product Development Milestones
- Appendix
Companies Mentioned
- 89bio Ltd
- AbbVie Inc
- ABIONYX Pharma SA
- Acasti Pharma Inc
- AD Pharmaceuticals Co Ltd
- Affina Biotechnologies Inc
- Akcea Therapeutics Inc
- Akeso Biopharma Inc
- Amarin Corp Plc
- Arrowhead Pharmaceuticals Inc
- AstraZeneca Plc
- AVVA Pharmaceuticals AG
- BCWorld Pharm Co Ltd
- BioRestorative Therapies Inc
- Boryung Pharmaceutical Co Ltd
- Cadila Healthcare Ltd
- Cadila Pharmaceuticals Ltd
- Cardax Inc
- Celon Pharma SA
- Centaurus Therapeutics Inc
- Centeer BioTherapeutics Ltd Co
- Chong Kun Dang Pharmaceutical Corp
- CJ HealthCare Corp
- Corbus Pharmaceuticals Inc
- Corvidia Therapeutics Inc
- CVI Pharmaceuticals US Inc
- Daewon Pharmaceutical Co Ltd
- Daewoong Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd
- Delivra Corp
- DongKoo Bio & Pharma Co Ltd
- Eli Lilly and Co
- Elyson Pharmaceutical Co Ltd
- Esperion Therapeutics Inc
- Gemphire Therapeutics Inc
- Gilead Sciences Inc
- Golden Biotechnology Corp
- Handok Inc
- Hanlim Pharm Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- Ildong Pharmaceutical Co Ltd
- Inovio Pharmaceuticals Inc
- InStar Technologies AS
- Jeil Pharmaceutical Co Ltd
- Jenrin Discovery Inc
- Jiangsu Hengrui Medicine Co Ltd
- Kolmar Pharma Co Ltd
- Kotobuki Pharmaceutical Co Ltd
- Kowa Co Ltd
- Krisani Bio Sciences Pvt Ltd
- Kuhnil Pharmaceutical Co Ltd
- Kyorin Pharmaceutical Co Ltd
- Kyung Dong Co Ltd
- LG Chem Ltd
- LipimetiX Development Inc
- Matinas BioPharma Holdings Inc
- Micelle BioPharma Inc
- Mochida Pharmaceutical Co Ltd
- MYR GmbH
- Nippon Chemiphar Co Ltd
- NorthSea Therapeutics BV
- NovalGen Ltd
- Novartis AG
- NuSirt Biopharma Inc
- Omeros Corp
- OncoImmune Inc
- Pfizer Inc
- Pharmena SA
- Regeneron Pharmaceuticals Inc
- Reneo Pharmaceuticals Inc
- Sequor Pharmaceuticals LLC
- Shanghai Institute of Pharmaceutical Industry
- Shanghai Junshi Bioscience Co Ltd
- Shenzhen Salubris Pharmaceuticals Co Ltd
- Shifa Biomedical Corp
- SJT Molecular Research SL
- Staten Biotechnology BV
- Suzhou Ribo Life Sciences Co Ltd
- Sveikatal Inc
- Tetranov International Inc
- Viking Therapeutics Inc
- Yuhan Corp
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ejhtz3
